Personalized Regimens for Managing Hemophilia A: Selecting an Optimal Recombinant FVIII Agent

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the role of FVIII therapy in managing bleeding in patients with hemophilia A
• Evaluate clinical trial data for new and emerging recombinant FVIII products for the prophylactic treatment of patients with hemophilia A
• Discuss the role of pharmacokinetic-tailored prophylaxis in selecting a recombinant FVIII product for the management of hemophilia A
• Develop personalized prophylactic treatment plans for patients with hemophilia A